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Abstract
Background: Glyoxalase 1 (Glo1) and glyoxalase 2 (Glo2) are ubiquitously expressed cytosolic enzymes that catalyze the
conversion of toxic a-oxo-aldehydes into the corresponding a-hydroxy acids using L-glutathione (GSH) as a cofactor. Human
Glo1 exists in various isoforms; however, the nature of its modifications and their distinct functional assignment is mostly
unknown.
Methodology/Principal Findings: We characterized native Glo1 purified from human erythrocytes by mass spectrometry.
The enzyme was found to undergo four so far unidentified posttranslational modifications: (i) removal of the N-terminal
methionine 1, (ii) N-terminal acetylation at alanine 2, (iii) a vicinal disulfide bridge between cysteine residues 19 and 20, and
(iv) a mixed disulfide with glutathione on cysteine 139. Glutathionylation of Glo1 was confirmed by immunological
methods. Both, N-acetylation and the oxidation state of Cys
19/20, did not impact enzyme activity. In contrast,
glutathionylation strongly inhibited Glo1 activity in vitro. The discussed mechanism for enzyme inhibition by
glutathionylation was validated by molecular dynamics simulation.
Conclusion/Significance: It is shown for the first time that Glo1 activity directly can be regulated by an oxidative
posttranslational modification that was found in the native enzyme, i.e., glutathionylation. Inhibition of Glo1 by chemical
reaction with its co-factor and the role of its intramolecular disulfides are expected to be important factors within the
context of redox-dependent regulation of glucose metabolism in cells.
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Introduction
Glyoxalases (Glo1, E.C. 4.4.1.5, and Glo2, E.C.3.1.2.6)
constitute an ubiquitous detoxification system that protects against
cellular damage caused by reactive 2-oxo-aldehydes such as
methylglyoxal (MGO). MGO originates mainly from non-
enzymatic degradation of triose phosphates but is also formed
during amino acid metabolism and acetone oxidation [1]. Glo1 (S-
D-lactoylglutathione lyase) and Glo2 (hydroxyacyl glutathione
hydrolase) convert the spontaneously formed hemithioacetal
between glutathione (GSH) and MGO into D-lactate and free
GSH. Thus, GSH acts as a physiological cofactor of Glo1 [2].
Glo1 is known to play a role in many diseases including diabetes
mellitus [3], Alzheimer’s disease [4], and cancer [5].
Although Glo1 is ubiquitously expressed, limited information is
available on how this enzyme is regulated in human cells.
Particularly, cells with increased glucose metabolism are suggested
to protect themselves against cellular damage by MGO through
up-regulation of Glo1 activity. That is most tumor cells, such as
cells derived from prostate, breast, and colon cancer, displayed
increased expression of Glo1 in conjunction with enhanced
anaerobic breakdown of glucose to lactate [5]. However, in
expression studies, cellular effects expected from reduced Glo1
activity and Glo1 knockdown such as increased MGO concentra-
tion revealed rather discordant findings [6,7]. Within this context,
GSH was proposed to exhibit other functions beyond its mere
anti-oxidative properties as enzyme co-factor and redox-regulator
[8].
The human enzyme Glo1 is a homodimeric Zn
2+- dependent
isomerase with two identical active sites at its dimer interface; the
two monomers are associated by non-covalent bonds [9]. The
derived translation product of the human GLO1 gene (Q04760)
consists of 184 amino acids. There are two genetic variants of Glo1
differing at position 111 with a glutamate-alanine substitution
(E111A) resulting in subsequent formation of three Glo1 isozymes
in heterozygotes. After putative posttranslational removal of N-
terminal methionine as suggested by Ridderstrom [10], the
calculated average masses of the monomers are 20,647.4 Da
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sequences. The molecular mass of the dimer was 46 kDa
determined by gel permeation chromatography [11].
Beside the known genetic variants (allozymes), a couple of
different isoforms of Glo1 have been described [12], but only few
studies addressed the nature of the enzyme’s polymorphism. The
N-terminal alanine residue was found to be blocked by an
unknown modification in the mature human protein [10]. Further,
at least four putative phosphorylation sites were deduced from the
amino acid sequence [11]. Indeed, phosphorylated Glo1 has been
recently detected in fibrosarcoma cell line L929 upon treatment by
tumor necrosis factor a (TNFa) [12,13]. A distinct phosphoryla-
tion site was identified at Thr
106 [14]. While phosphorylation
seemed to impact the pattern of MGO-derived advanced glycation
end products (AGE), no effect upon the catalytic activity of the
enzyme itself was found that would explain the elevated MGO
concentration found in TNFa-treated cells [13].
Reversible inactivation of Glo1 was observed upon exposure of
cells to extra-cellular nitric oxide (NO) which was strictly
dependent on the level of GSH indicating that Glo1 is an NO-
responsive protein [15,16]. It was suggested that the observed
inhibiting modification of the enzyme was brought about by
nitrosylation of distinct amino acid residues near the active site of
Glo1. Studies on Glo1 Cys-mutants revealed that cysteine
residues, primarily Cys
139, may be involved in the NO-
responsiveness of Glo1 [12].
To our knowledge, other covalent modifications of the human
enzyme have not yet been described. Most investigations on Glo1
did not rely on mass spectrometry and its unique potential to
identify posttranslational modifications by interpretation of
characteristic mass differences and their localization after digest
of the protein. There are only few reports on Glo1 applying mass
spectrometry at all, such as studies of Glo1 from E. coli which inter
alia described the non-covalent dimerization of the enzyme as a
function of pH [17,18].
In the present study, we identified and localized four
posttranslational modifications of Glo1 by means of mass
spectrometry and immunological approaches: (i) removal of N-
terminal methionine, (ii) N-terminal acetylation, (iii) a vicinal
disulfide bridge at Cys
19/20, and (iv) glutathionylation at Cys
139.
Glutathionylation of Glo1 strongly inhibited enzyme activity at
physiologically relevant concentration of GSH. Our results suggest
direct regulation of the enzyme in response to the cellular redox
state, which will have crucial importance for elucidating the
functions of Glo1 in vivo.
Results
Evidence of posttranslational modification of Glo1 by ESI-
FTICR-MS analysis
Purified Glo1 from human erythrocytes was subjected to
analysis by direct-infusion ESI-FTICR (Figure 1A). At acidic
conditions, a charge distribution of +14 - +22 was observed. ESI
mass deconvolution demonstrates the presence of two species with
an average molecular mass of 20,629.7 Da and 20,687.4 Da
(Figure 1B), respectively, exhibiting a mass difference of 58 Da.
This mass difference would be in accordance with the two possible
monomers of the enzyme that differ at position 111, carrying
either alanine or glutamic acid. To our knowledge, this is the first
time the exact molecular mass of the two allelic monomers of
human Glo1 was determined by mass spectrometry.
In fact, after suggested posttranslational methionine removal
[10], average masses of the two monomer allozymes were
supposed to be 20,589.3 Da or, 20,647.4 Da, respectively,
deduced from the nucleotide sequence of human Glo1 [19].
Compared with the theoretical value, we found a mass difference
of +40 Da proposing posttranslational modification of the enzyme.
Along with the two peaks of the monomer allozymes in the
deconvoluted spectrum, we observed two additional peaks of 1/5
signal intensity with a mass difference of +305 Da compared to
each of the two monomers (Figure 1B). The signal intensities of
these ‘‘twin’’ peaks were different from preparation to preparation,
ranging from not detectable till up to three times higher than the
non-modified form.
After b-mercaptoethanol (b-ME) treatment, subsequent analy-
sis by direct-infusion ESI-FTICR mass spectrometry followed by
ESI mass deconvolution obtained average mass values of
20,631.8 Da and 20,689.5 Da for the monomers of the two
allozymes (Figure 1C) resulting in a net-mass difference of 42 Da
instead of the expected 40 Da found earlier. The mass difference
of 2 Da after reduction was attributed to the presence of an
intramolecular disulfide in a first instance. The M+305-Da peaks
were not detected which indicated an oxidative modification of
the enzyme.
Posttranslational modifications of Glo1 were localized by
MALDI-TOF/TOF analysis and nano-LC-ESI-MS/MS
The peptide mass fingerprint (PMF) obtained with MALDI-
TOF/TOF-MS/MS analysis of a tryptic digest of the non-reduced
enzyme preparation (Figure 2) was identified as Glo1 with a score
of 84 searched against SwissProt 54.7 database using an in-house
mascot search engine [20].
In agreement with ESI-FTICR analysis of the native prepara-
tion, fragment m/z 2687.5 matched the expected mass for the N-
terminal fragment increased by 40 Da (Figure 2A). As illustrated
in Figure 2B, tandem mass spectrometry of the fragment m/z
2687.5 displayed the distinct y-series D-E-A-A-L-S which
unambiguously confirmed the N-terminal tryptic peptide of
Glo1, H-AEPQPPSGGLTDEAALSCCSDADPSTK-OH.
We found two discrepancies in the specific mass differences
between the MS/MS-fragments of that peptide compared with the
theoretical values deduced from sequence data. These were (i)
confirmation of Met
1 removal evident by comparison with the
expected overall peptide mass of the N-terminus; (ii) the observed
mass difference of 406 Da instead of 408 Da between m/z 1024
and 618 for the C-C-S-D-fragment of the N-terminus that
suggested a disulfide-bridge located between these two vicinal
cysteine residues; and (iii) the mass difference of 242 Da instead of
200 Da between m/z 2687 and 2445 as the theoretical deduced
value for the N-terminal fragment A–E (Figure 2B), suggesting an
acetylated terminal alanine.
N-terminal posttranslational modification of human Glo1 has
been reported earlier by Ridderstroem et al. [10]. This N-terminal
modification had no impact on enzymatic activity and was absent
in the recombinant enzyme in E. coli, indicating a modification
specific to eukaryotic cells. We identified this modification here
being an N-terminal acetylation. In E. coli, N-terminal acetylation
of proteins does not occur, while up to 85% of eukaryotic proteins
are modified with an acetyl group after N-terminal cleavage of
methionine [21].
We searched in the non-reduced preparation for other cleavage
products that masses were increased by the observed mass
difference of 305 Da and identified m/z 2038.9 as a potential
candidate for the peptide H-GFGHIGIAVPDVYSACK-OH plus
305 Da (Figure 2A). H-GFGHIGIAVPDVYSACK-OH with an
expected m/z 1734 was detected in the digest as well. Accurate
mass measurement by direct infusion ESI-FTICR analysis
confirmed the peak matching the expected mass for that peptide
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139, with m/z
510.48970 and a deviation of 0.4 ppm for the fourfold-charged
and with m/z 680.31777 and a deviation of 1.3 ppm for the
threefold-charged species, respectively.
The b- and y-fragments of MALDI-TOF/TOF-MS/MS of m/
z 2038.9 were in accordance with this assumption (Figure 2C): the
mass differences in the y-series with y8 to y13 and the b-series b5 to
b12, i.e. the sequence corresponding to I-GI-A-V-PD-V, confirmed
Figure 1. Glo1 ESI-FTICR mass spectrum. (A) Original spectrum, peaks are labeled according to their charge. The two isoforms of Glo1 and the
corresponding glutathionylated forms are clearly separated at a resolution of .25,000. (B) Deconvoluted spectrum of Glo1, m/z axis not to scale.
Peaks are labeled with the average mass. Processing by XMass Software clearly extracts the two separated allozymes. Right-hand side, the
corresponding glutathionylated forms are shown. (C) Deconvoluted spectrum of a purified Glo1 preparation after b-mercaptoethanol treatment. The
determined average mass differs by 2 Da compared with the native monomeric forms, the glutathionylated forms were not detected in this
preparation.
doi:10.1371/journal.pone.0010399.g001
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differences of y-ions to the precursor ion m/z 2038.9 were shifted
by an increase of 305 Da from y8 on, i.e. y13 exhibited an m/z
1640.8 instead of the theoretical m/z 1336, while the b-series was
in accordance with the theoretically expected values up to b12.
This indicated a covalently attached 305 Da- modification near
the C-terminus of the peptide involving the YSACK residue. After
reduction and alkylation of the tryptic digest and analysis by
MALDI-TOF/TOF-MS/MS, the target fragment at m/z 2038.9
was not detected; only the alkylated GFGHIGIAVPDVYSACK of
m/z 1790 was found instead indicating the presence of a disulfide
as modification of this peptide fragment.
These results were confirmed by nano-LC-ESI-QqTOF-MS/
MS analysis (Figure 3A) where the b-series clearly confirmed the
peptide sequence of I-G-I-A-V-P-D-V-Y and the corresponding y-
series unambiguously restricted the site of a 305 Da- modification
to the C-K sequence at the C-terminus.
Nano-LC-ESI-QqTOF-MS/MS analysis further revealed a
fifth, optional modification of Glo1, namely another disulfide
bridge between H-GFGHIGIAVPDVYSACK-OH and H-
CDFPIMK-OH, i.e. Cys
139 and Cys
61 (Figure 3B). According to
the b- and y-series obtained after MS/MS, these two tryptic
peptides evidently assembled the observed species at m/z 2586.
Thiol-disulfide exchange has already been shown to occur in
several proteins during sample preparation [22,23], in particular
when thiol and disulfide are closely located to each other which is
not the particular case with Cys
139 and Cys
61 [24]. Often, these
artifacts are observed at much lower intensity than natively bound
disulfides, which would be in accordance with the fact that we did
not detect this tryptic fragment in our MALDI-TOF analyses or
nano-LC analysis after alkylation only without reduction.
However, disulfide exchange of Cys
139 or Cys
61 involving Cys
19
or Cys
20 was not observed.
The vicinal disulfide bridge does not affect enzyme
activity
Following treatment of reduced Glo1 with phenylarsine oxide
(PAO) which is known to react specifically with vicinal sulfhydryl
groups of proteins to form thioarsine rings [25], we found no
change in enzyme activity (data not shown). These results indicate
that modifying the vicinal disulfide alone is not sufficient to impact
enzyme activity of Glo1.
Glutathionylation was confirmed by immuno-detection
of bound GSH
Further confirmation of glutathionylation of Glo1 was obtained
by Western blotting with anti-GSH antibodies (Figure 4A). Anti-
GSH antibodies were reactive to native Glo1 and BSA-GSH
prepared as control, while no immuno-reactivity was observed
when native Glo1 was incubated with b-ME prior to electropho-
resis or BSA samples were probed with anti-Glo1 antibodies.
These results clearly indicate that Glo1 is indeed a target protein
for glutathionylation.
The observed glutathionylation at Cys
139 is unlikely to be an
artifact. Purification of the enzyme was carried out under non-
denaturing, reducing conditions strictly avoiding any use of GSH.
Furthermore, we found no evidence in our data that glutathio-
nylation happens on any other cysteine of our protein. Human
Glo1 has four cysteine residues, of which Cys
139 is conserved from
bacteria to human among the known species. Cys
19 and Cys
20
were found so far in mouse, rat, simian, and human Glo1, while
Cys
61 is unique to humans and possibly could be involved in
substrate binding inside the hydrophobic pocket [24]. The vicinal
Cys
19 and Cys
20 are probably not accessible due to their protecting
disulfide bridge, but Cys
61 would be generally amenable to bind
GSH.
Incubation of Glo1 with GSSG alters enzyme activity
We measured the activity of purified Glo1 upon incubation with
a reducing agent (Figure 4B). Enzyme activity was increased up to
80% in the presence of b-ME in a concentration-dependent
manner. We observed variation in specific activity and degree of
b-ME-responsive activation in different enzyme preparations. To
show the reversibility of activation by provoking thiol-disulfide
exchange with the active enzyme species (denominated as Glo1-A),
we incubated Glo1-A with increasing concentrations of GSSG and
found almost complete inactivation of the enzyme (denominated
as Glo1-B, Figure 4C). These results were corroborated also by
Western blot. Moreover, reduction by b-ME was found to change
the kinetic parameters of the enzyme preparation toward higher
Vmax and lower Km values indicating that the substrate affinity
strongly depends on the degree of glutathionylation (Figure 4D).
In conclusion of our results, we suggest that Glo1 exists in vivo in
a non-glutathionylated, highly active form (A-enzyme), and a
glutathionylated, less active, form (B-enzyme).
Discussion
The cytoplasm is thought to be a reducing environment and,
hence, disulfides are expected to be deliberately formed by
oxidation involving specialized systems, such as the thioredoxin
system, should they occur. Therefore, to find disulfide bonds and
glutathionylation in Glo1 under regular conditions (assuming it is
mostly cytoplasmic) clearly indicates a redox-regulation mecha-
nism of enzyme activity.
Glutathionylation regulates Glo1 activity
Since its discovery, glutathionylation of enzymes and transcrip-
tion factors is being recognized as a central mechanism by which
changes in the intracellular redox state may be transduced into
functional cellular responses [26–28]; interaction of GSH with
proteins was already suggested in 1985 by Grimm et al. [29].
Figure 2. MALDI-TOF MS analyses of the non-reduced tryptic digest of Glo1. (A) Full Scan, m/z range 1500–3000. The presented m/z range
of the MALDI-TOF spectrum contains the three important peptide fragments to this investigation. The first ion, [M+H]
+=2687.09 (N), represents the
N-terminus with N-acetylation and a vicinal disulfide-bridge on Cys
19/20. The second peptide, [M+H]
+=2038.91 (&), contains the suggested binding
site for GSH, namely Cys
139. The third ion, [M+H]
+=1733.84 (m), is the same peptide, non-glutathionylated. (B): Tandem-MS analysis of
(M+H)
+=2687.09, the N-terminal peptide of Glo1, the sequence (HAc)-AEPQPPSGGLTDEAALSCCSDADPSTK-(OH) carrying the vicinal disulfide. D-E-A-
A-S-L identified the peptide being the N-terminal tryptic cleavage product of Glo1. The y-series reveals a mass difference of 42 Da (acetylation)
between the precursor ion and the last y-ion (y27) at the N-terminus. The 2 Da mass shift for the fragment C-C-S-D (y6 and y10), suggests a vicinal
disulfide-bridge between the two cysteines. (C) Tandem-MS analysis of [M+H]
+=2038.91, the tryptic peptide with glutathionylated Cys
139. The y- and
b-series confirm the identity of the peptide H-GFGHIGIAVPDVYSAC(GCE)K-(OH) with the partial sequence of V-DP-V-A-IG-I. Up to b12, the fragment
pattern matches the non-modified series of the N-terminus of the peptide, but the mass difference of 874 instead of 569 between the b12 fragment
and the precursor ion suggests a covalent attachment of GSH to this peptide sequence before GFGHIGIAVPDV. The y-series suggests GSH-attachment
before y8, i.e. before GFGHIGIAV.
doi:10.1371/journal.pone.0010399.g002
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glyceraldehyde-3-phosphate dehydrogenase [30], human p53
[31], and NFkB [32], whereas activated few others such as
human oncogene Ras [26,28]. In particular, several glycolytic
enzymes were found to be regulated by glutathionylation, such as
glyceraldehyde-3-phosphate dehydrogenase, aldolase, phospho-
glycerate kinase, pyruvate kinase, triose phosphate isomerase, and
lactate dehydrogenase [33,34]. It was further suggested that
glutathionylation could coordinate cellular metabolism in response
to oxidative stress by modulating glycolysis [34]. Interestingly,
Fratelli et al. found an unidentified protein of 46 kDa also to be
glutathionylated [35], i.e. the same molecular mass as the Glo1
dimer, and suggested that there are proteins ‘‘constitutively’’
glutathionylated in absence of oxidative stress. Moreover, the
second enzyme of the glycolysis-associated Glo system, Glo2, has
been found earlier to be glutathionylated in vitro but a physiological
importance was deemed unlikely [36].
We demonstrate here that human Glo1 can be reversibly
glutathionylated and its activity is suppressed by glutathionylation.
Within cells, the ratio of GSH/GSSG is assumed to be about
Figure 3. Nano-LC-ESI-qTOF-MS/MS analyses. (A) Tryptic peptide with glutathionylated Cys
139 (m/z 2038.9) with corresponding b- and y-series.
The y- and b-series confirm the identity of the peptide H-GFGHIGIAVPDVYSAC(GCE)K-(OH) with the partial sequences of I-G-I-A-V-P-D-V and PD-V-Y-S-
AC(GCE)-K, respectively. Up to b12, the fragment pattern matches the series of the N-terminus of the peptide, the mass difference of 479 Da instead of
174 Da for the y3-y1 fragment locates the attachment of GSH to this peptide sequence at Cys
139. (B) Disulfide bridge between the two tryptic
peptides H-GFGHIGIAVPDVYSACK-(OH) and H-CDFPIMK-(OH) (Cys
61/139, m/z 2584.3). The sequences of b4 up to b13 and y1 to y6 unambiguously
identify the two peptides; the presence of y13 confirms the covalent disulfide bond.
doi:10.1371/journal.pone.0010399.g003
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oxidative stress [28]. An inhibiting influence of excess GSH on
Glo1 activity was reported earlier as competitive inhibition to the
hemi-mercaptal substrate [37], while low concentration was found
to favor MGO detoxification via the aldose reductase (ALR2)
pathway, possibly as a function of substrate concentration in
consequence to hemi-thioacetal formation [38]. However, GSH at
concentrations up to 2 mM enhanced Glo1 activity in vitro [39].
Thiol-exchange mechanisms have been discussed for glutathio-
nylation, but, unless the protein has an unusual redox potential,
they would require high concentration of GSSG, which is not
likely to occur in vivo [40]. Formation of reactive sulfhydryl
intermediates of protein-SH and GSH most likely precedes protein
glutathionylation in vivo, such as S-nitrosyl (–SNO) and other
(sulfenic acid –SOH, thiyl radical, thiosulfinate –S(O)SR, or
sulfenyl-amide, cyclic-S–N–CO–). Increase in the GSH/GSSG
ratio or enzymatic reactions involving protein disulfide isomerase,
glutaredoxin 1 (GRx1) or thioredoxin, were suggested to restore
the protein sulfhydryls to their reduced state. Currently, proposed
candidates to catalyze S-glutathionylation in vivo include glutathi-
one-S-transferase pi and GRx1. [28]
Nitrosylation is one way suggested to activate protein thiols
prior to glutathionylation. Human Glo1 has been shown earlier to
be responsive to nitrosylation by S-nitroso-gluthathione (GSNO):
the presence of a faster migrating isoform of Glo1 on non-
denaturing gels was observed after treatment of L929 cells with
increasing concentration of GSNO [12]. The authors concluded
that the NO-mediated modification of enzymatic activity of Glo1
is possibly the consequence of structural changes that are induced
by this modification. However, considering the increased net
charge of the detected isoform, glutathionylation was denied,
which would in fact have lead to a decrease of net charge. In
Figure 4. Glutathionylation of Glo1 by immunoreactivity and activity assays. (A) Anti-GSH mab display immunoreactivity against native
Glo1. Purified human Glo1 separated by SDS-PAGE under non-reducing conditions was probed with the anti-GSH mab (a) or anti-Glo1 mab (b),
respectively, followed by incubation with HRP-labelled goat anti-mouse Ig. Protein staining was accomplished by Coomassie Brilliant Blue R250 (c).
(M) and (D) represent the monomer and dimer of Glo1. Lane 1: Glo1: 10 mg (a); 0.5 mg (b) and 5 mg (c); lane 2: Glo1: 10 mg +20 mM b-ME (a); 0.5 mg (b)
and 5 mg (c); lane 3: BSA: 20 mg (a); 20 mg (b) and 20 mg (c); lane 4: BSA-GSH: 20 mg (a); 20 mg (b) and 20 mg (c). (B) Activation of Glo1 by b-ME. Glo1
was incubated with increasing concentrations of b-ME and activity was assayed after dialysis. Data is presented as the mean 6 SD of three
independent experiments. (***=p,0.001; *=p,0.05 vs. blank). (C) Incubation of Glo1 with oxidized glutathione causes enzyme inhibition. Activity
of reduced Glo1 was evaluated after incubation with 5 mM and 20 mM GSSG. The native, b-ME-treated (20 mM), and GSSG-treated (20 mM) enzyme,
respectively, were subjected to non-reducing SDS-PAGE followed by Western blotting. The membrane was stained for protein with Ponceau S (a) and
probed with the anti-GSH antibody (b). The enzyme activity of all samples was measured (c). Data are presented as mean 6SD of three independent
experiments. (***=p,0.001). (D) Kinetic analysis of native and reduced Glo1. Enzyme activity of 70 mU Glo1 was determined after incubation with
increasing equimolar concentrations of MGO/GSH: non-treated enzyme (#);b-ME-treated enzyme (&). Kinetic data are expressed as Vmax (mmol/min)
and Km (mM) values.
doi:10.1371/journal.pone.0010399.g004
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occur at Cys
139; other modifications such as the state of oxidation
of the vicinal Cys
19 and Cys
20 could contribute to the net charge as
well.
Glutathionylation vs. disulfide bridge on Cys
139
Beside glutathionylation on Cys
139, we found this same residue
to form an optional disulfide bridge with Cys
61. Since Cys
61 was
found so far in human only, this disulfide would be unique to
human. Consequently, Cys
139 might be involved in at least two
alternatively occurring posttranslational modifications of Glo1 in
human, underpinning the crucial role this residue obviously plays
in regulation of the enzyme. We found evidence for the presence
of at least two modifications of Cys
139 in native human Glo1
beside the free thiol, i.e. the mixed disulfide with GSH, and bound
in a disulfide bridge with Cys
61.
In a study by Lan [41], the presence of a flexible loop near the
active site of Glo1 was proposed which was specified later on by
Creighton and coworkers [24] (Figure 5). The hydrogen bonding
pattern of this loop (residues 153–160) in the open and closed
conformations suggested that the loop is open in the absence of
bound ligand, which enables the substrate (or inhibitor) to enter
the active site. After binding of enediolate analogues, the loop
closes above the active site [24]. Though for interaction with the
inner sphere ligands of the essential metal Zn (Figure 5), an S
substituent on glutathione is necessary, an S substituent was not
required for ligation of GSH alone [42]. Thus, if GSH simply
ligates with Glo1, the flexible loop closes and prevents other
substrates from entering. GSH as enzyme ligand was found to
interact mainly with the guanidino group of Arg
38 and the amide
group of Asn
104 forming hydrogen bonds with both, the
carboxylate and the amino group of the c-glutamate of GSH
[9], but not Cys
139.
According to [24], Cys
139 should be rather located near the
flexible loop (Figure 5). Covalent binding of GSH to Cys
139 as
found in our experiments might also induce an inactive
conformation by moving the flexible loop over the active site of
the enzyme and thus bring about suppression of enzyme activity
by preventing the hemithioacetal substrates from entering, such as
MGO-GSH which was tested in our experiments. A disulfide
between Cys
61/139 (Figure 5) could even close the barrel
completely.
Figure 5. 3D structure of a Glo1 dimer according to [24]. Colored residues show the position of Zn-ligands (blue) and GSH-ligands (magenta).
The transparent blue cone placed in the upper monomer mimics the general position of a ligand in the barrel containing the active site. The flexible
loop that closes upon ligation over the barrel is colored in gold, the cysteine residues in shades of red. We suggest that covalent binding of GSH to
Cys
139 brings about a conformational change to the flexible loop that might subsequently close the barrel.
doi:10.1371/journal.pone.0010399.g005
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hypothesis (Figure 6). As a result of the calculations it turned out
that the geometry of the backbone of the protein itself did not
significantly change upon of GSH binding to Cys
139 with
exception of the loop involving residues 153–160. Root mean
square deviation of the loop backbone itself indicated an obvious
structural change when comparing the experimentally determined
configuration [24] with the computed glutathionylated protein
(Figure 6A): the distance between the active Zn
2+ ion and the Ca-
atom of Lys
157 became smaller suggesting a movement of the
flexible loop directed towards the active site of the protein upon
glutathionylation (Figure 6B) which would be in full agreement
with our assumptions.
De Hemptinne et al. [12] investigated the role of all four
cysteines in NO-mediated modification of Glo1 and found that
replacement of Cys
61 by exchange with alanine did not prevent
from NO-modification after GSNO treatment, while the Cys
139 .
Ala mutant, was impaired for NO-mediated modification.
Notably, we found Cys
139 as the target for glutathionylation. It
was suggested that GSNO treatment-mediated change in enzyme
activity was brought about by a conformational change in
agreement with our hypothesis concerning the flexible loop.
Figure 6. Molecular simulations of Glo1 dimer. The grey area denotes the heating phase (cf. text). (A) Root mean square distances (rmsd) of the
backbone atoms of the loop (153–160) in the glutathionylated protein (green) and the unmodified protein (blue). The rmsd of the rest of the protein
remains stable. (B) Distance between the Zn
2+ ion and the Ca atom of Lys
157. The distance in the glutathionylated protein (red) is smaller than that in
the unmodified protein (black) over the entire simulation period.
doi:10.1371/journal.pone.0010399.g006
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formation of an intramolecular disulfide bridge in many proteins
[43]. It has been shown that formation of an intramolecular
disulfide after glutathionylation in low molecular weight protein
tyrosine phosphatase (LMW-PTP) was involved in rescuing
enzyme activity via restoring the reduced state after oxidation of
the cysteine located in the catalytic pocket [44]. An intriguing
thought would be that formation of a Glo1 intramolecular
disulfide between Cys
61 and Cys
139 could exhibit a similar
function, e.g. to reduce bound GS(H) and subsequently remove
it in a first step to restore enzyme activity.
The vicinal disulfide Cys
19/20
Vicinal cysteines are rather rare in proteins, the more if found
near the N-terminus distant from the active site of the enzyme.
The redox state of these cysteins is likely having other functions
than mere protection from degradation [45,46]. An interaction
with the enzyme’s environment in a redoxstate-relevant situation
becomes even more indicative considering that the Glo1 N-
terminus is exposed to the surface in the tertiary structure of the
enzyme (Figure 5).
Vicinal disulfides are generally suggested to exert different
functions, such as receptor and co-factor binding, or a role in
oxidative folding. Oxidized vicinal disulfide bridges impact protein
folding; the peptide is forced in a distorted trans-conformation.
Due to the conserved tertiary structure of the vicinal disulfide turn
and the dramatic change that can be expected upon reduction of
it, this structural element was suggested to act as a redox-activated
conformational switch [45]. Disruption of such thiols was shown to
inactivate the redox-sensitive protein phosphatase [47] as well as
squalene monooxygenase [48] and affected the function of many
other proteins [45,49,50].
De Hemptinne et al. [12] foundthecysteine residuesCys
19/20/139
together involved in responsiveness of Glo1 to GSNO-treatment
in human red blood cells. NO-mediated modification was
maintained for Cys
19 and Cys
20 single mutants, impaired for the
double mutant Cys
19/20 and completely absent in triple mutants of
Cys
19/20/139. It wassuggestedthat Cys
139 interacts witheitherCys
19
or Cys
20 for this modification of the protein.
The vicinal thiol-specific reagent phenylarsine oxide (PAO)
significantly enhanced glutathionylation in oxidatively stressed
cells [51]. Again, in a reducing environment such as the cytoplasm,
disulfide bonds are expected to serve a certain function; an
intriguing thought would be that Cys
19 and Cys
20 could play a role
in mediating the proposed glutathionylation or, respectively,
dethiolation of Cys
139 itself, which could eventually explain the
differential interaction of these three cysteine residues in NO-
mediated modification of Glo1 [12] and be consistent with our
results, where enzyme activity was not suppressed with PAO only.
Conclusions
The active role of GSH in redox regulation of different
processes was recently addressed in several studies. Thus, our
findings of a posttranslational modification of Glo1 by GSH could
be important for the many diseases, in which altered Glo1 activity
was observed and, consequently, obviously might need to be
regulated in response to the redox state of tissues beyond protein
expression, such as tumor cell proliferation [6], diabetes [52],
congenital nonspherocytic hemolytic anemia [53], and numerous
others.
In particular, reversible inhibition of Glo1 by glutathionylation
is certainly expected to impact detoxification of cellular MGO as
depleted GSH and elevated MGO concentration were character-
ized as key events in glyoxalase inhibition [54]. High concentra-
tions of MGO are toxic to cells, for instance by secondary
depletion of ATP, modulation of mitochondrial membrane
potential, induction of apoptosis, and ROS-production [55].
Recent results showed that MGO also has regulatory functions
on proteins such as activation of transcription factors [55],
modulation of enzyme activities [56], and inhibition of NF-kB
p65 binding to DNA [57]. Under anaerobic conditions, glycolysis
is triggered in the cell and MGO production is enhanced, so that
the cell could use redox-regulation of Glo1 to respond immediately
to enhance detoxification with MGO without detour of transcrip-
tion and protein synthesis.
Very clearly, we showed that oxidation of Cys
139 by means of
glutathionylation caused by GSSG has impact on enzyme activity.
Three of the five identified posttranslational modifications are in
fact disulfides, strongly suggesting that Glo1 is indeed regulated in
response to the redox state of the cell.
Materials and Methods
Materials and chemicals
Ammonium acetate (puriss. p.a., ACS reagent, $98.0%),
iodoacetamide (purum $98.0%), formic acid (puriss. p.a., for
mass spectroscopy), trifluoroacetic acid (TFA, for UV-spectrosco-
py), and ammonium bicarbonate (NH4HCO3, $99.5%) were
obtained from Fluka Chemie GmbH (Buchs, Switzerland). Porcine
trypsin (Sequencing Grade Modified Trypsin) was purchased from
Promega (Madison, USA). Acetonitrile (LC-MS grade) was
obtained from Biosolve B.V. (Valkenswaard, Netherlands). Pipette
tips for sample preparation (C18, ZipTip
TM) were obtained from
Millipore (Billerica, USA.). All aqueous solutions were prepared
with deionized water having a resistance of at least 18 MV xc m
(Elga–Labwater, Celle, Germany). a-Cyano-4-hydroxycinnamic
acid (CHCA) for MALDI analyses were purchased from Bruker
Daltonics GmbH (Bremen, Germany). Rotiphorese Gel 30 (acryl
amide and N,N’-Methylene bisacryl amide 37,5:1), reduced L-
glutathione (GSH), soybean trypsin inhibitor, and carboanhydrase
were purchased from Roth GmbH (Karlsruhe, Germany).
Oxidized glutathione (GSSG) was obtained from Boehringer
(Mannheim, Germany). Anti-GSH mouse monoclonal antibody
(anti-GSH mab) was obtained from Virogen (Watertown, USA)
and anti-Glo1 monoclonal antibody (Clone 4C10, anti-Glo1 mab)
from BioMac GmbH (Leipzig, Germany). Horseradish (HRP)-
labeled goat anti-mouse Immunoglobulin (Ig) was delivered by
Dako (Glostrup, Denmark). Dithiothreitol (DTT), b-mercaptoeth-
anol (b-ME), 3,39-diaminobenzidine (DAB), Phenylarsine oxide
(PAO), S-hexylglutathione sepharose, S-hexylglutathione, methyl-
glyoxal (MGO), Phenylmethylsulfonylfluoride (PMSF), Tween 20,
and bovine serum albumin (BSA) were purchased from Sigma
(Taufkirchen, Germany). Coomassie Brilliant Blue R250 and
Ponceau S were ordered from Serva (Heidelberg, Germany). All
other chemicals were of analytic reagent grade.
For visualization of the 3D structure of Glo1 dimer according to
[24], Open Source RasWin Molecular Graphics, windows version
2.7.5., was used. The protein data bank file 1QIN.pdb used for
Figure 5 was downloaded on 04/09/2008 from http://www.pdb.
org/.
The same file was used for calculations of molecular dynamics
with the modeling package MOE 2008.10 (Chemical Computing
Group, Inc. Montreal, Canada). After removal of the crystallo-
graphic water molecules, hydrogen atoms were added and
Amber99 charges assigned. The simulation of glutathionylation
on Cys
139 was performed using the molecular editor module of
MOE. For MD-simulation, the system was slowly heated up to
300 K during 300 ps. The system was simulated in vacuo for
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manual. A snapshot was saved every 0.1 ps. Before analysis, the
backbone atoms of each snapshot were aligned to the starting
structure.
Purification of Glo1
Glo1 was purified from human erythrocytes under conditions
preventing from oxidation according to Mannervik et al. [58]
yielding 90% enzyme purity (SDS-PAGE). Specific enzyme
activity of various Glo1 preparations ranged between 450 and
700 U/mg. Fresh human erythrocytes were obtained from the
Blood Transfusion Centre of the Medical Faculty of the University
of Leipzig and were handled according to regulations of the local
authorities, including ethics approval of our study by the Ethics
Committee of the University of Leipzig (Vote No. 146-2006) and
written informed consent from all participants.
Mass spectrometry of the intact monomer by ESI-FTICR-
MS
Purified Glo1 dissolved in 20 mM ammonium acetate/aceto-
nitrile 2:1 with 0.1% or 1% formic acid (v/v), respectively, was
subjected to flow injection analysis by ESI-FTICR-MS in positive
mode. For all ESI analyses, a BioApex II ESI-FTICR-MS
instrument (Bruker Daltonics, Bremen, Germany) with XMass
software was used, equipped with a 7.4 Tesla magnet and an
electrospray ion source (Agilent, Waldbronn, Germany). For
treatment with b-ME, 0.1 mg freeze-dried Glo1 was dissolved in
20 mM ammonium acetate, pH 7.0, and incubated at room
temperature in 25 mM b-ME prior to measurement.
Tryptic digest of Glo1, alkylation and reduction of
disulfide bonds
Freeze-dried Glo1 (0.1 mg) was dissolved in 3 mM ammonium
bicarbonate (ABC), pH 8.5, and was divided into two equal
aliquots. To one aliquot, 1 M DTT was added and the reaction
mixture was subsequently incubated at 95uC for 5 min. After
centrifugation, the sample was incubated with iodoacetamide
solution (27.5% w/v in water). The sample was incubated at room
temperature and conditioned with 150 mM ABC. The second
aliquot was incubated with 3 mM ABC only. Both aliquots were
processed further identically by incubation with trypsin solution
(20 ng/ml in 3 mM ABC) at 37uC overnight. After centrifugation,
formic acid was added and the samples were dried in a speed vac.
Samples were dissolved again in 0.1% formic acid and purified on
C18 ZipTip. Peptides were eluted with 0.5% formic acid in 80%
acetonitrile and subjected to analysis by mass spectrometry. The
non-reduced sample was then reduced following the procedure
using iodoacetamide and DTT described above and analyzed
again. In a second experiment, alkylation with iodoacetamide only
was carried out to confirm obtained results for the non-reduced
preparation.
Analysis of tryptic digests by mass spectrometry
The tryptic digests were analyzed by MALDI-TOF/TOF-MS/
MS in positive ion mode, (4700 proteomics Analyzer Applied
Biosystems, Applera Deutschland GmbH, Darmstadt, Germany)
with a-cyano-4-hydroxycinnamic acid (CHCA) as matrix. ESI-
FTICR-MS analyses of the digests were carried out as described
above for the intact monomer.
Alternatively, an HPLC 1100 series (Agilent Technologies
GmbH, Waldbronn, Germany) equipped with a Zorbax 300 SB-
C18 column (column dimensions 150 mm675 mm, particle size
3.5 mm; Agilent Technologies GmbH, Waldbronn, Germany), was
coupled on-line to the nanoESI-source (Proxeon, Odense, Den-
mark) of a Qq-TOF-type mass spectrometer (QSTAR Pulsar I,
Applied Biosystems, Applera Deutschland GmbH, Darmstadt,
Germany). 1 pmol of the non-reduced tryptic digest was dissolved
in 3% acetonitrile and injected. Eluents were 3% acetonitrile
containing 0.1% formic acid (eluent A) and 0.1% formic acid in
acetonitrile (eluent B). The flow rate was 0.25 ml/min. The sample
was loaded isocratically with 3% eluent B for 10 min. Elution was
performed by a 60-min gradient (1–45% eluent B in 30 min, 45–
75% eluent B in 10 min, 75–90% eluent B in 10 min, 90–3%
eluent B in 10 min). Ion spray voltage was set to 2200 V. The two
most intense, double to quintuple charged signals detected in a
TOF experiment were selected to perform automated MS/MS
analysis of each parent ion for 1 s each in the m/z range from 70
to 1700. The spectra were interpreted with Analyst QS software
(Applied Biosystems, Applera Deutschland GmbH, Darmstadt,
Germany) and MASCOT database (Matrix Science Ltd., London,
UK).
Glyoxalase assays
Glo1 activity was measured according to Mannervik et al. [58].
To study the effect of glutathione depletion, enzyme activity of
100 ml purified Glo1 (5 units) with a specific activity of 570 U/mg
was measured after incubation without and with 5 mM and
20 mM b-ME followed by dialysis (4uC, 2 h) against 50 mM
sodium phosphate buffer, pH 7.0.
The effect of GSSG on enzyme activity was assessed by activity
measurement following incubation of de-glutathionylated enzyme
with increasing concentration of GSSG. To this end, after
treatment with 20 mM b-ME, Glo1 was incubated with 5 mM
and 20 mM GSSG at room temperature.
Aliquots (20 mg) of native, b-ME- and GSSG-treated enzyme
(each at a concentration of 20 mM), were subjected to SDS-PAGE
under non-reducing conditions followed by Western blotting. The
membrane was stained for protein with Ponceau S and
subsequently probed with the anti-GSH Ab. The enzyme activity
of all samples was determined.
Kinetic analyses
Enzyme activity (DE/min) was determined upon incubation of
non-treated and b-ME-treated enzyme with increasing equimolar
concentrations of MGO/GSH. Reduction of Glo1 (5 units) was
carried out by incubation with 20 mM b-ME (30 min, 22uC),
followed by dialysis against 50 mM sodium phosphate buffer,
pH 7.0 (2 h at 4uC). Kinetic data were fitted to the Michaelis-
Menten equation using the Marquardt-Levenberg method with
simple weighing. A goodness-of-fit criterion (Akaike’s information
criterion, AIC) was used for falsification of sigmoid enzyme
kinetics. The quality of the fit was characterized by 95%
confidence intervals of the estimated parameters. The analysis
was performed using the Enzyme Kinetics Module of SigmaPlot
(Systat Inc., San Jose, USA).
Western blot of Glo1
Proteins were separated by SDS-PAGE in pore gradient gels
(4% to 20% T) under non-reducing conditions and blotted to
cellulose nitrate membranes (Whatman Schleicher & Schuell,
Dassel, Germany) stained with Ponceau S. After blocking with 3%
defatted milk over night, the membrane was probed with mouse
anti-GSH mAB (1 mg/ml), and with mouse anti-Glo1 mAB (1 mg/
ml) in 50 mM sodium phosphate, 150 mM sodium chloride,
pH 7.0 (PBS), containing 3% BSA and 0.1% Tween 20 (PBS-T-
BSA) for 1.5 h. After washing with PBS containing 0.1% Tween
20 (PBS-T), the membrane was incubated with horse radish
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with DAB/H2O2. Proteins separated by SDS were stained with
Coomassie Brilliant Blue R250. Soybean trypsin inhibitor
(20 kDa) and carboanhydrase (29 kDa) were used as molecular
mass markers.
Coupling of glutathione to bovine serum albumin
BSA (5 mg/ml) was incubated with the cross-linking reagent N-
succinimidyl-3-(2-pyridyldithio) propionate (SPDP) (Pierce, Bonn,
Germany) (0.34 mg in 100 ml ethanol) in 50 mM sodium
phosphate buffer, pH 7.0 at 20uC for 30 min. The sample was
dialyzed against incubation buffer and reacted with 5 mg GSH.
The reaction mixture was dialyzed against phosphate buffer
overnight. The formation of pyridine-2-thione was assessed at
343 nm to calculate bound GSH. GSH/BSA ratio of the final
product was 2.5 mol/mol.
In this report, all amino acids were numbered according to
Ref_prot NP_006699.
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